Skip to content

Bolus eptifibatide versus bolus plus infusion

A comparison of complication & major cardiovascular events of bolus eptifibatide versus bolus plus infusion of eptifibatide in Primary PCI in patients with acute ST-elevation myocardial infarction

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20110512006463N3
Enrollment
163
Registered
2021-03-17
Start date
2018-04-01
Completion date
Unknown
Last updated
2021-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Acute ST elevation myocardial infarction. Condition 2: Acute ST elevation myocardial infarction. Condition 3: Acute ST elevation myocardial infarction. Condition 4: Acute ST elevation myocardial infarction. ST elevation (STEMI) myocardial infarction of unspecified site ST elevation (STEMI) myocardial infarction of anterior wall ST elevation (STEMI) myocardial infarction of inferior wall ST elevation (STEMI) myocardial infarction of other sites

Interventions

Intervention 1: Intervention group will receive 2 bolus doses of eptifibatide (Merk) with dose of 180mcg/kg with 10 minute interval. Then they will receive 2mcg/kg/min of eptifibatide infusion
totally 1 vial of 75mg/cc (short term protocol). Intervention 2: Control group: will receive 2 bolus doses of eptifibatide (Merk) with a dose of 180mcg/kg with a 10-minute intervals. Then they will re

Sponsors

Deputy of research and technology of Alborz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with symptoms of ischemic heart attack that last no longer than 12 hours with 1 mm ST elevation in at least 2 limb leads or 2 mm ST elevation in at least 2 precordial leads who are candidates for Primary PCI intervention.

Exclusion criteria

Exclusion criteria: Not acceptance of informed consent History of sensitivity to eptifibatide, heparin or aspirin Recent treatment with warfarin (INR>2), fibrinolythics or other IIbIIIa inhibitors Platelet 200mmHg, or DBP>110mmHg)

Design outcomes

Primary

MeasureTime frame
Vascular or bleeding complication. Timepoint: During in-hospital admision. Method of measurement: Questionnaire and physical exam.

Secondary

MeasureTime frame
Death. Timepoint: 2 days and 6 months after intervention. Method of measurement: Questionnaire, Electronic file.;Myocardial infarction. Timepoint: 2 days and 6 months after intervention. Method of measurement: ECG and increase in CKMB.;Need for target lesion revascularization (TLR). Timepoint: 2 days and 6 months after intervention. Method of measurement: Questionnaire, Electronic file.;Need for target vessel revascularization (TVR). Timepoint: 2 days and 6 months after intervention. Method of measurement: Questionnaire, Electronic file.;Need for coronary artery bypass graft (CABG). Timepoint: 2 days and 6 months after intervention. Method of measurement: Questionnaire, Electronic file.;Cerebrovascular accidents. Timepoint: 2 days and 6 months after intervention. Method of measurement: Questionnaire, Electronic file.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Fatemeh Sehati

?Alborz University of Medical Sciences

F_sehati@yahoo.com+98 26 3457 0030

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026